Iteos Therapeutics, Inc. ( (ITOS) ) has released its Q3 earnings. Here is a breakdown of the information Iteos Therapeutics, Inc. presented to ...
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia ...
What Factors Have Led to iTeos Therapeutics Inc (ITOS) Stock Trading -53.01% Below Its 52-Week High?
On Friday, iTeos Therapeutics Inc (ITOS) stock saw a modest uptick, ending the day at $8.81 which represents a slight increase of $0.36 or 4.26% from the prior close of $8.45. The stock opened at ...
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares ...
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with ...
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback